Bank of New York Mellon Corp Decreases Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Bank of New York Mellon Corp trimmed its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 169,346 shares of the company's stock after selling 2,307 shares during the period. Bank of New York Mellon Corp owned about 0.59% of Krystal Biotech worth $26,530,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Crossmark Global Holdings Inc. grew its stake in Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after purchasing an additional 121 shares during the period. Perigon Wealth Management LLC increased its holdings in Krystal Biotech by 1.5% during the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock worth $1,200,000 after buying an additional 123 shares during the last quarter. KBC Group NV raised its position in Krystal Biotech by 25.9% in the third quarter. KBC Group NV now owns 642 shares of the company's stock worth $117,000 after acquiring an additional 132 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Krystal Biotech by 3.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company's stock valued at $840,000 after acquiring an additional 153 shares during the last quarter. Finally, Pier 88 Investment Partners LLC grew its position in shares of Krystal Biotech by 5.1% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 3,530 shares of the company's stock valued at $643,000 after acquiring an additional 170 shares during the period. 86.29% of the stock is owned by institutional investors.

Remove Ads

Krystal Biotech Stock Performance

NASDAQ KRYS traded down $0.99 on Thursday, hitting $177.40. The stock had a trading volume of 192,688 shares, compared to its average volume of 289,967. The firm has a 50-day moving average of $162.66 and a 200-day moving average of $174.19. The company has a market capitalization of $5.11 billion, a price-to-earnings ratio of 59.33 and a beta of 0.87. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. During the same period in the prior year, the business earned $0.30 earnings per share. Krystal Biotech's revenue for the quarter was up 116.4% compared to the same quarter last year. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital upped their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup upped their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Finally, Jefferies Financial Group started coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $220.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).